Do the first, second and third trimester maternal serum hepcidin concentrations clarify obstetric complications?

Basit Öğe Kaydı
dc.contributor.authorSimavli, Serap
dc.contributor.authorDerbent, Aysel Uysal
dc.contributor.authorKeskin, Esra Aktepe
dc.contributor.authorGumus, Ilknur Inegol
dc.contributor.authorUysal, Sema
dc.contributor.authorTurhan, Nilgun
dc.date.accessioned2025-10-24T18:09:45Z
dc.date.available2025-10-24T18:09:45Z
dc.date.issued2015
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractObjective: To evaluate whether first, second, and third-trimester maternal serum hepcidin levels are different in pregnancies with and without adverse pregnancy outcomes (APO). Methods: A 165 nullipar pregnant women were included in this prospective cohort study. Serum hepcidin, ferritin, IL-6, C-reactive protein (CRP) and Hb values were measured at 11-14, 24-28, and 30-34 weeks of gestation. The relation between these parameters and APO and neonatal outcomes were investigated. Preterm delivery, intrauterine growth restriction, preeclampsia, gestational hypertension and placental abruption were determined as adverse pregnancy outcomes. Results: The risk of APO was three times higher in women with high IL-6 levels in the second trimester. High hepcidin levels in the second trimester were associated with a 1.6 times increased risk of APO. Newborns of women with high IL-6 levels in the third trimester had a 1.6-fold increased risk of neonatal complications. High ferritin levels in the third trimester were associated with minimally increased risk of neonatal complications. Conclusions: Mean serum hepcidin levels were similar in all pregnant women, however, elevated second trimester serum hepcidin and IL-6 levels were associated with a higher risk of APO and high third trimester hepcidin, ferritin and IL-6 levels were associated with higher risk of neonatal complications.
dc.description.sponsorshipFatih University [P53010902-2]
dc.description.sponsorshipThis work was supported by the Scientific Research Fund of Fatih University under the project number P53010902-2.
dc.identifier.doi10.3109/14767058.2014.935759
dc.identifier.endpage857
dc.identifier.issn1476-7058
dc.identifier.issn1476-4954
dc.identifier.issue7-8
dc.identifier.pmid24946025
dc.identifier.scopus2-s2.0-84930883453
dc.identifier.scopusqualityQ1
dc.identifier.startpage854
dc.identifier.urihttps://doi.org/10.3109/14767058.2014.935759
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3803
dc.identifier.volume28
dc.identifier.wosWOS:000358701200019
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofJournal Of Maternal-Fetal & Neonatal Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20251023
dc.subjectAdverse pregnancy outcomes; ferritin; hepcidin; neonatal complications
dc.titleDo the first, second and third trimester maternal serum hepcidin concentrations clarify obstetric complications?
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu